Pretreatment characteristics and early indicators of long-term efficacy of cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (rmSCCHN).
Ulrich Keilholz
Consultant or Advisory Role - Merck
Honoraria - Merck Serono
Research Funding - Merck Serono
Maren Knoedler
Honoraria - Merck Serono
Ines Redlich
No relevant relationships to disclose
Thomas Christoph Gauler
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono